The chart of InspireMD Inc (NSPR) shows a double top with $3.24 target or 3.00% above today’s $3.15 share price. The 7 months chart pattern indicates low risk for the $5.18 million company. It was reported on Jan, 11 by Finviz.com. If the $3.24 price target is reached, the company will be worth $155,400 more. Double tops are rare but powerful chart patterns. About 228,459 shares traded hands or 23.32% up from the average. InspireMD Inc (NYSEMKT:NSPR) has declined 70.42% since June 7, 2016 and is downtrending. It has underperformed by 77.84% the S&P500.
Analysts await InspireMD Inc (NYSEMKT:NSPR) to report earnings on March, 27.
InspireMD Inc (NYSEMKT:NSPR) Ratings Coverage
Out of 2 analysts covering InspireMD (NYSEMKT:NSPR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $4.0 is the highest target while $4.0 is the lowest. The $4 average target is 26.98% above today’s ($3.15) stock price. InspireMD has been the topic of 2 analyst reports since January 7, 2016 according to StockzIntelligence Inc. The rating was initiated by Rodman & Renshaw with “Buy” on Thursday, January 7. H.C. Wainwright initiated InspireMD Inc (NYSEMKT:NSPR) on Thursday, January 7 with “Buy” rating.
According to Zacks Investment Research, “InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company’s initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. It focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid and peripheral procedures. InspireMD Inc. is headquartered in Tel Aviv, Israel.”
NSPR Company Profile
InspireMD, Inc., incorporated on February 29, 2008, is a medical device company. The Firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The Company’s MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet mesh and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company’s MGuard coronary product, MGuard Prime Embolic Protection System (MGuard Prime EPS), is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.